Cipla Limited — Others, 16-07-2025: Shareholders meeting

Cipla's 89th Annual General Meeting (AGM) highlighted a strong FY25 performance, with revenue reaching INR 27,548 Cr (up 8% YoY), EBITDA at INR 7,128 Cr (up 14% YoY), and PAT soaring to INR 5,273 Cr (up 28% YoY), reflecting record EBITDA margins. The company affirmed its market leadership in India, North America, and South Africa, alongside consistent quality with all five USFDA-audited facilities receiving a 'VAI' status. Strategic focuses include respiratory medicine, AMR initiatives, and future pipeline development in diagnostics, mRNA, and biosimilars. Shareholders approved the financial statements, dividend declaration, and director re-appointment, signaling confidence in the company's operational health and growth trajectory.